BCR/ABL Quantitative PCR major and /or minor
Test Code
P BCR ABL
Test Synonyms
Philadelphia Chromosome; major t(9;22) e13/e14(p210), minor t(9;22) e1 (p190)
Associations
Chronic myelogenous leukemia (CML), Acute lymphoblastic leukemia (ALL), Allogeneic bone marrow transplantation, Minimal residual disease (MRD), Molecular remission
Methodology
Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) for BCR/ABL major t(9;22) e13/e14(p210) and minor t(9;22) e1 (p190) fusion gene transcipts.
CPT Codes
Please contact a client service specialist at 800.932.2943
Turnaround Time
3-5 days
Specimen Requirements
- 10.0 mL (min. 9.0 mL) peripheral blood in EDTA
- 5.0 mL (min. 2.5 mL) bone marrow in EDTA
Specimen Stability
- Specimen must be received by MPLN within 48 hours of collection
- Stable at 2-8°C
Storage & Handling
Causes for Rejection
Specimen >48 hours old; Specimen clotted; Specimen stored or shipped at incorrect temperature; Specimen in incorrect anticoagulant; Insufficient specimen volume
Reference Range
Positive: major or minor BCR/ABL fusion quantified relative to ABL
Negative: major or minor BCR/ABL fusion not detected, less than 0.001% BCR/ABL
Negative: major or minor BCR/ABL fusion not detected, less than 0.001% BCR/ABL
Related Content
Cytogenetics
Flow Cytometry
BCR/ABL by FISH
BCR/ABL disease monitoring by quantitative PCR
ABL kinase gene mutation for Gleevec resistance
Flow Cytometry
BCR/ABL by FISH
BCR/ABL disease monitoring by quantitative PCR
ABL kinase gene mutation for Gleevec resistance
Description
Molecular detection of the BCR/ABL fusion gene transcript (e13a2, e14a2, e1a2) in patients with a Philadelphia (t[(9;22)(q34;q11.2)]) positive leukemia. The translocation is found in >99% of CML patients, ~20% of adult acute lymphoblastic leukemia (ALL), ~5% of pediatric ALL, and ~2% of acute myeloid leukemia (AML).
The primary clinical utilities for BCR/ABL quantitative PCR testing include (1) identfication of fusion gene transcript and determination of baseline level of BCR-ABL expression in newly diagnosed CML patients, and (2) the monitoring of patients for molecular evidence of minimal residual disease (MRD) or molecular remission in response to tyrosine kinase inhibitor (TKI) therapy or allogeneic stem cell transplantation.
The primary clinical utilities for BCR/ABL quantitative PCR testing include (1) identfication of fusion gene transcript and determination of baseline level of BCR-ABL expression in newly diagnosed CML patients, and (2) the monitoring of patients for molecular evidence of minimal residual disease (MRD) or molecular remission in response to tyrosine kinase inhibitor (TKI) therapy or allogeneic stem cell transplantation.
References
Jabbour E et al. (2008). Molecular monitoring in chronic myeloid leukemia. Cancer. 112:2112-2118.
Trademarks
Gleevec® is a registered trademark of the Novartis Pharmaceuticals Corporation.